Company news
Livzon Pharmaceutical Group, Inc. news in 2022
Livzon Pharmaceutical Group, Inc.'s news releases, calls and decks from 2022, newest first.
Interim Report 2022
August 9, 2022
2022 First quarterly report
April 21, 2022
Livzon Pharmaceutical was recognized as the National Enterprise Technology Center with High Scores
April 20, 2022
A Recombinant SARS-Cov-2 Fusion Protein Vaccine (V-01) developed and manufactured by Livzon has shown good protective effects against the Omicron variant in a phase III clinical booster trial
April 20, 2022
Rapid Test for 2019-nCoV-2 Antigen (Lateral Flow) approved by China NMPA.
April 20, 2022
V-01 as a Sequential Booster Can Produce Good Protection against Omicron ---- Latest Phase III Data of COVID-19 Vaccine by Livzon Pharma
February 18, 2022